RLMD
Relmada Therapeutics Inc.
$3.83
+$0.28(+7.89%)
33
Overall
40
Value
36
Tech
23
Quality
Market Cap
$50.78M
Volume
715.64K
52W Range
$0.24 - $5.12
Target Price
$9.00
Company Overview
| Mkt Cap | $50.78M | Price | $3.83 |
| Volume | 715.64K | Change | +7.89% |
| P/E Ratio | -0.6 | Open | $3.51 |
| Revenue | -- | Prev Close | $3.55 |
| Net Income | $-80.0M | 52W Range | $0.24 - $5.12 |
| Div Yield | N/A | Target | $9.00 |
| Overall | 33 | Value | 40 |
| Quality | 23 | Technical | 36 |
No chart data available
About Relmada Therapeutics Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest News
Relmada’s New Phase 3 Bladder Cancer Trial Adds a Fresh Catalyst to Its Pipeline
TipRanks Clinical-Trials-Auto-Generated Newsdesk•19 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RLMD | $3.83 | +7.9% | 715.64K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Relmada Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW